Schneeweiss S - Search Results

1

Early steps in the development of a claims-based targeted healthcare safety monitoring system and application to three empirical examples.

Wahl PM, Gagne JJ, Wasser TE, Eisenberg DF, Rodgers JK, Daniel GW, Wilson M, Schneeweiss S, Rassen JA, Patrick AR, Avorn J, Bohn RL. Wahl PM, et al. Among authors: schneeweiss s. Drug Saf. 2012 May 1;35(5):407-16. doi: 10.2165/11594770-000000000-00000. Drug Saf. 2012. PMID: 22489640

2

Clozapine use and risk of diabetes mellitus.

Wang PS, Glynn RJ, Ganz DA, Schneeweiss S, Levin R, Avorn J. Wang PS, et al. Among authors: schneeweiss s. J Clin Psychopharmacol. 2002 Jun;22(3):236-43. doi: 10.1097/00004714-200206000-00002. J Clin Psychopharmacol. 2002. PMID: 12006892

3

Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study.

Schneeweiss S, Hasford J, Göttler M, Hoffmann A, Riethling AK, Avorn J. Schneeweiss S, et al. Eur J Clin Pharmacol. 2002 Jul;58(4):285-91. doi: 10.1007/s00228-002-0467-0. Epub 2002 Jun 12. Eur J Clin Pharmacol. 2002. PMID: 12136375

4

Pharmaceutical cost containment with reference-based pricing: time for refinements.

Schneeweiss S, Maclure M, Dormuth C, Avorn J. Schneeweiss S, et al. CMAJ. 2002 Nov 26;167(11):1250-1. CMAJ. 2002. PMID: 12451080 Free PMC article. No abstract available.

5

Measuring the cost-effectiveness of lipid-lowering drugs in the elderly: the outcomes research and economic analysis components of the PROSPER trial.

Avorn J, Benner J, Ford I, Ganz DA, Gaw A, Glynn RJ, Jackson J, Lagaay AM, Schneeweiss S, Walley T, Wang PS; Outcomes Research Working Group and the PROSPER Study Group. Avorn J, et al. Among authors: schneeweiss s. Control Clin Trials. 2002 Dec;23(6):757-73. doi: 10.1016/s0197-2456(02)00228-3. Control Clin Trials. 2002. PMID: 12505250

6

Improved comorbidity adjustment for predicting mortality in Medicare populations.

Schneeweiss S, Wang PS, Avorn J, Glynn RJ. Schneeweiss S, et al. Health Serv Res. 2003 Aug;38(4):1103-20. doi: 10.1111/1475-6773.00165. Health Serv Res. 2003. PMID: 12968819 Free PMC article.

7

Determinants of selective cyclooxygenase-2 inhibitor prescribing: are patient or physician characteristics more important?

Solomon DH, Schneeweiss S, Glynn RJ, Levin R, Avorn J. Solomon DH, et al. Among authors: schneeweiss s. Am J Med. 2003 Dec 15;115(9):715-20. doi: 10.1016/j.amjmed.2003.08.025. Am J Med. 2003. PMID: 14693324

8

Clinical and economic consequences of a reimbursement restriction of nebulised respiratory therapy in adults: direct comparison of randomised and observational evaluations.

Schneeweiss S, Maclure M, Carleton B, Glynn RJ, Avorn J. Schneeweiss S, et al. BMJ. 2004 Mar 6;328(7439):560. doi: 10.1136/bmj.38020.698194.F6. Epub 2004 Feb 24. BMJ. 2004. PMID: 14982865 Free PMC article. Clinical Trial.

9

Use of the case-crossover design to study prolonged drug exposures and insidious outcomes.

Wang PS, Schneeweiss S, Glynn RJ, Mogun H, Avorn J. Wang PS, et al. Among authors: schneeweiss s. Ann Epidemiol. 2004 Apr;14(4):296-303. doi: 10.1016/j.annepidem.2003.09.012. Ann Epidemiol. 2004. PMID: 15066610

10

Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.

Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, Avorn J. Solomon DH, et al. Among authors: schneeweiss s. Circulation. 2004 May 4;109(17):2068-73. doi: 10.1161/01.CIR.0000127578.21885.3E. Epub 2004 Apr 19. Circulation. 2004. PMID: 15096449

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

630 results

Search Page

Filters